Comparison of the Profile of the AML Drug Midostaurin (Rydapt®) As a Kinase Inhibitor with Those of Its Predominant Primary Human Metabolites
- Resource Type
- Abstract
- Source
- In
Blood 8 December 2017 130 Supplement 1:1383-1383 - Subject
- Language
- ISSN
- 0006-4971